CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

10800	Companies
233619	Keywords
162289	Articles
124731	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/24/2025 at 19:00, 1 year 1 month ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 1 year 1 month ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior
PRESS RELEASE

published on 06/11/2025 at 07:30, 1 year 1 month ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
BRIEF

published on 06/06/2025 at 17:50, 1 year 1 month ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
BRIEF

published on 06/04/2025 at 20:26, 1 year 2 months ago

CROSSJECT launches a capital increase of nearly 5 million euros

Investment Pharmaceutical Capital Increase Preferential Subscription Right ZEPIZURE®
PRESS RELEASE

published on 06/04/2025 at 20:21, 1 year 2 months ago

Launch of a capital increase with preferential subscription rights for nearly 5 million euros
CROSSJECT announces capital increase with preferential subscription rights totaling nearly 5 million euros. Existing shareholders and Vatel Capital commit to subscribe 76.4% of the amount. Subscription price set at 1.40 euros. Subscription period from June 12 to June 20, 2025

Capital Increase Subscription Period Preferential Subscription Rights Crossject Vatel Capital
BRIEF

published on 06/03/2025 at 07:35, 1 year 2 months ago

Maxim Group Recommends CROSSJECT with €4.00 Target Price

Buy Recommendation Crossject ZEPIZURE® Needle-free Auto-injector Maxim Group
PRESS RELEASE

published on 06/03/2025 at 07:30, 1 year 2 months ago

Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Maxim Group initiates coverage of CROSSJECT with BUY recommendation and €4.00 target price. CROSSJECT, a specialty pharma company, looks forward to positive developments with FDA and pipeline

FDA Buy Recommendation Specialty Pharma Crossject Maxim Group
BRIEF

published on 05/27/2025 at 07:35, 1 year 2 months ago

CROSSJECT optimizes its production with the ZENEO® Nest

CDMO Funding Production Crossject ZENEO® Nest
BRIEF

published on 05/20/2025 at 07:35, 1 year 2 months ago

CROSSJECT Plans €5 Million Capital Increase to Boost EUA Approval Activities

Capital Increase Crossject ZEPIZURE® Gemmes Venture EUA Approval

Accesswire

Published on 08/05/2026 at 02:10, 2 hours 44 minutes ago

Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance
Published on 08/04/2026 at 22:30, 6 hours 24 minutes ago

Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares
Published on 08/04/2026 at 22:00, 6 hours 54 minutes ago

Lockheed Martin and NioCorp Sign MOU
Published on 08/04/2026 at 16:25, 12 hours 29 minutes ago

ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Published on 08/04/2026 at 15:00, 13 hours 54 minutes ago

Infield Minerals Expands Land Position at the Kings Canyon Gold Project in Utah

View all ACCESSWIRE

EQS Group

Published on 08/04/2026 at 22:03, 6 hours 50 minutes ago

#FutureFresenius: Excellent Q2 performance demonstrates structural step-up – Guidance raised
Published on 08/04/2026 at 22:01, 6 hours 52 minutes ago

EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance
Published on 08/04/2026 at 20:05, 8 hours 48 minutes ago

Hard Rock Cafe and Coca-Cola® Launch Hard Rock Rising Music Competition for Emerging Artists
Published on 08/04/2026 at 19:40, 9 hours 13 minutes ago

NNS acquires shares in OCI
Published on 08/04/2026 at 19:39, 9 hours 14 minutes ago

EQS-Adhoc: Basler AG financial results for the first 6 months of 2026: Strong business performance in the first half of the year; company raises its 2026 forecast once again

Les Echos

Published on 08/04/2026 at 19:16, 9 hours 38 minutes ago

Covivio - 2026 Half-year financial report
Published on 08/04/2026 at 18:32, 10 hours 21 minutes ago

Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 11 hours 9 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 08/04/2026 at 16:00, 12 hours 54 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 08/04/2026 at 08:15, 20 hours 39 minutes ago

Covivio - Conditions of availability of the 2026 Half-year report

View all LES ECHOS COMFI WIRE